← Leaderboards
Jun Qi
Dana-Farber Cancer Inst
$6,834,111
Attributed
$9,695,361
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,695,361 · 8
By mechanism
R01$8,105,958 · 4
U54$507,443 · 1
U01$478,100 · 1
P50$451,854 · 1
P01$152,006 · 1
Top collaborators
- Scott A Armstrong6 shared
- Derek Ronald Duckett4 shared
- Brian Abraham1 shared
- Adam David Durbin1 shared
- Jianguo Tao1 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- James E Bradner$6,722,003
- Richard M Stone$3,984,410
- Emily Heikamp$430,358
Others in their field
Top investigators on “Epigenetic Process”
- James E. Gern · University Of Wisconsin-Madison$115,652,679
- Richard A Gibbs · Baylor College Of Medicine$86,065,396
- Lisa P Jacobson · Johns Hopkins University$67,179,266
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$58,922,015
- Leonardo Trasande · New York University School Of Medicine$52,109,279
- Linda M Brzustowicz · Rutgers The St Univ Of Nj New Brunswick$47,855,284
Research focus
Epigenetic ProcessSmall MoleculeIn VivoInsightBiologyClinical TrialsCellsMalignant NeoplasmsProteinsTranslationsLaboratoriesClinical InvestigationPharmaceutical PreparationsIn VitroInhibitor/AntagonistBiologicalBindingChromatinLysineLeadGeneticNovel TherapeuticsJointsPharmacology
Grant awards (24)
Targeting EP300 epigenomic control in neuroblastoma$768,713
R01 · FY2025 · CA
Transcriptional and Epigenetic Adaptation as Novel Therapeutic Vulnerabilities for Mantle Cell Lymphoma$472,337
R01 · FY2024 · CA
Transcriptional and Epigenetic Adaptation as Novel Therapeutic Vulnerabilities for Mantle Cell Lymphoma$487,253
R01 · FY2023 · CA
EZH2 in cancer biology and novel inhibitors$528,530
R01 · FY2022 · CA · contact PI
Transcriptional and Epigenetic Adaptation as Novel Therapeutic Vulnerabilities for Mantle Cell Lymphoma$487,253
R01 · FY2022 · CA
Targeting DOT1L for Degradation in MLL-rearranged Leukemia$395,996
R01 · FY2022 · CA
EZH2 in cancer biology and novel inhibitors$536,827
R01 · FY2021 · CA · contact PI
Transcriptional and Epigenetic Adaptation as Novel Therapeutic Vulnerabilities for Mantle Cell Lymphoma$497,197
R01 · FY2021 · CA
Targeting DOT1L for Degradation in MLL-rearranged Leukemia$404,076
R01 · FY2021 · CA
EZH2 in cancer biology and novel inhibitors$535,301
R01 · FY2020 · CA · contact PI
Transcriptional and Epigenetic Adaptation as Novel Therapeutic Vulnerabilities for Mantle Cell Lymphoma$513,372
R01 · FY2020 · CA
Targeting DOT1L for Degradation in MLL-rearranged Leukemia$404,076
R01 · FY2020 · CA
Targeting BRDT (testis-specific bromodomain) for Male Contraception$230,666
P50 · FY2020 · HD · contact PI
EZH2 in cancer biology and novel inhibitors$492,047
R01 · FY2019 · CA · contact PI
Targeting DOT1L for Degradation in MLL-rearranged Leukemia$391,951
R01 · FY2019 · CA
Targeting DOT1L for Degradation in MLL-rearranged Leukemia$239,963
R01 · FY2019 · CA
Targeting BRDT (testis-specific bromodomain) for Male Contraception$221,188
P50 · FY2019 · HD · contact PI
Core E: Experimental Therapeutics Core$152,006
P01 · FY2019 · CA · contact PI
EZH2 in cancer biology and novel inhibitors$546,990
R01 · FY2018 · CA · contact PI
Targeting DOT1L for Degradation in MLL-rearranged Leukemia$404,076
R01 · FY2018 · CA
Targeting BRDT (testis-specific bromodomain) for Male Contraception$223,311
U54 · FY2018 · HD · contact PI
Targeting BRDT (testis-specific bromodomain) for Male Contraception$284,132
U54 · FY2017 · HD · contact PI
Selective inhibition of BRDT for male contraception$240,876
U01 · FY2016 · HD · contact PI
Selective inhibition of BRDT for male contraception$237,224
U01 · FY2015 · HD · contact PI